A lentiviral vector containing a muscle-specific promoter and sequence-optimized full-length DMD transgene could constitute an effective cell-mediated gene therapy to treat all DMD patients, regardless of their DMD mutation. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.